Retinal Vein Occlusion
📧 Sign up to get email alerts when something new happens for Retinal Vein Occlusion.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2025-04-14EMA Application withdrawn: Skojoy (aflibercept) — Amgen Technology (Ireland) UC
EMA has withdrawn the marketing authorization application for Skojoy (aflibercept) submitted by Amgen Technology (Ireland) UC. The applicati…
-
CLINICAL_TRIALS withdrawal · 2009-02-04Clinical Trial Update: Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.) [Phase 2]
A Phase 2 open-label trial evaluating anecortave acetate (15 mg) for retinal vein occlusion has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2008-08-12Clinical Trial Update: Parnaparin vs Aspirin in the Treatment of Retinal Vein Occlusion [Phase 3]
A Phase 3 trial comparing parnaparin to aspirin for retinal vein occlusion was terminated.